Coaxing cancer control by modulating COX-2

2019 ◽  
Vol 11 (497) ◽  
pp. eaax9566 ◽  
Author(s):  
Rajan P. Kulkarni
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Mouse Models ◽  
Cancer Control ◽  
Cyclooxygenase 2 ◽  
Ductal Adenocarcinoma ◽  
Cox 2

Mouse models of pancreatic ductal adenocarcinoma respond to immunotherapy when given in combination with the cyclooxygenase-2 inhibitor celecoxib.

scholarly journals Preclinical mouse models for immunotherapeutic and non-immunotherapeutic drug development for pancreatic ductal adenocarcinoma

2020 ◽  
Vol 3 ◽  
pp. 7-7
Author(s):  
Mengni He ◽  
MacKenzie Henderson ◽  
Stephen Muth ◽  
Adrian Murphy ◽  
Lei Zheng
Keyword(s):  
Drug Development ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Mouse Models ◽  
Ductal Adenocarcinoma

scholarly journals EGFR, but not COX‑2, protein in resected pancreatic ductal adenocarcinoma is associated with poor survival

2019 ◽  
Author(s):  
Johan Fagman ◽  
David Ljungman ◽  
Peter Falk ◽  
Britt‑Marie Iresj� ◽  
Cecilia Engstr�m ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Ductal Adenocarcinoma ◽  
Poor Survival ◽  
Cox 2

1004 INHIBITION OF CYCLOOXYGENASE-2 (COX-2); AN OPPORTUNITY FOR BLADDER CANCER CONTROL

2009 ◽  
Vol 8 (4) ◽  
pp. 371
Author(s):  
S. Kontos ◽  
A. Kominea ◽  
G. Koritsiadis ◽  
V. Simaioforidis ◽  
S. Koritsiadis ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cancer Control ◽  
Cyclooxygenase 2 ◽  
Cox 2

scholarly journals MiR-142-3p is downregulated in aggressive p53 mutant mouse models of pancreatic ductal adenocarcinoma by hypermethylation of its locus

2018 ◽  
Vol 9 (6) ◽  
Author(s):  
Jack D. Godfrey ◽  
Jennifer P. Morton ◽  
Ania Wilczynska ◽  
Owen J. Sansom ◽  
Martin D. Bushell
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Mouse Models ◽  
Mutant Mouse ◽  
Ductal Adenocarcinoma
Sign in / Sign up

Export Citation Format

Share Document